Analyst consensus rating
Crescent Biopharma Analyst Rating: none
CBIO is rated none by 5 analysts with a $30.60 target. As of 2026-08-20.
Direct answer
Crescent Biopharma's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $30.60.
Forecast evidence checked August 20, 2026.
Get free Crescent Biopharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $16.90
- Average price target
- $30.60
- High price target
- $35.00
- Low price target
- $27.00
- Low target gap
- +59.8%
- Target upside
- +81.1%
- High target gap
- +107.2%
- Target range width
- 47.4%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- August 20, 2026
- Valid through
- August 27, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Crescent Biopharma?
Crescent Biopharma has a verified none consensus. The same dataset has an average price target of $30.60.
How far are Crescent Biopharma's low and high targets from the recorded price?
The low target implies +59.8%, while the high target implies +107.2%.
How many analysts are included in Crescent Biopharma's consensus?
The verified consensus includes 5 analysts.
How is Crescent Biopharma's target upside or downside calculated?
The average target of $30.60 is divided by the recorded price of $16.90, then one is subtracted to produce +81.1%. This does not guarantee a future return.
When was Crescent Biopharma's analyst forecast verified?
The data was verified on 2026-08-20. The dataset is valid through 2026-08-27.